Pharmacodynamics of dersimelagon
No treatment-related effects on melanin density were observed following single doses of dersimelagon (Part A). In Part E, apparent treatment-related increases in melanin density during the treatment period were observed in participants receiving 150 and 300 mg of dersimelagon compared with those receiving placebo (Fig. Mean percent change from baseline in average melanin density over time (Part E). Note: In participants receiving 300 mg of dersimelagon, 4 did not take study drug on day 14, and 2 did not take study drug on days 13 and 14. In participants receiving 450 mg of dersimelagon, all were Fitzpatrick skin type V, and 1 participant did not take study drug on days 12, 13, and 14